Abstract：
Lung cancer is the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for approximately 85 % of all lung cancers and having a poor treatment and prognosis. Conventional clinical chemotherapy and immunotherapy are challenged by systemic toxicity and drug resistance, so researchers are increasingly focusing on antibody-drug conjugate (ADC), an innovative concept combining chemotherapy and targeted therapy, in which a drug selectively binds to antigens on the surface of a tumor cell via antibodies, which internalize the ADC, and then transfers the ADC to the lysosome via the endosomes to degrade the drug and kill the tumor cell. Despite the promising nature of ADCs, no ADC product for any indication including NSCLC has been approved for marketing by the FDA to date. In this review, we summarize the main advantages of ADCs and discuss in depth the design of the most desirable ADCs for NSCLC therapy. In addition to preclinical studies, we focus on the current state of clinical research on ADCs as interventions for the treatment of NSCLC by summarizing real-time clinical trial data from ClinicalTrials.gov, and reasonably speculate on the direction of the design of future generations of ADCs.
摘要：
肺癌是癌症死亡的主要原因，非小细胞肺癌（NSCLC）约占所有肺癌的85％，治疗和预后不良。常规临床化疗和免疫治疗受到全身毒性和耐药性的挑战,因此，研究人员越来越关注抗体-药物偶联物（ADC），结合化疗和靶向治疗的创新概念，其中药物通过抗体选择性地与肿瘤细胞表面的抗原结合，将ADC内在化，然后通过内体将ADC转移到溶酶体以降解药物并杀死肿瘤细胞。尽管ADC很有前途，迄今为止,FDA尚未批准用于任何适应症(包括NSCLC)的ADC产品上市.在这次审查中,我们总结了ADC的主要优势，并深入探讨了NSCLC治疗最理想的ADC的设计。除了临床前研究,我们通过总结ClinicalTrials的实时临床试验数据，重点关注ADC作为NSCLC治疗干预措施的临床研究现状。并合理推测未来几代ADC的设计方向。
